Q-omics provides the consensus-scored RSPH14 profile across patient tissues and cancer cell-line models. RSPH14 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RSPH14 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, RSPH14 RNA expression shows 14,545 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, KICH, and TGCT as cancer lineages where RSPH14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RSPH14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RSPH14 survival associations across molecular data types. RSPH14 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RSPH14 RNA expression–survival associations across cancer types. High RSPH14 expression shows unfavorable associations in LGG, UVM and LIHC, but favorable associations in KIRP, READ and SARC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RSPH14 RNA expression.
This table summarizes RSPH14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RSPH14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RSPH14 shows lower tumor expression in KICH and LUAD and higher tumor expression in COAD, LIHC, THCA and STAD. The KICH box plot shows higher RSPH14 RNA expression in normal versus tumor tissue (log2 FC = −2.139, t-test p < 0.001).
This table shows molecular features associated with RSPH14 in patient tissues and cancer cell lines. In patient samples, RSPH14 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, RSPH14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Lymphoma.
